丙型肝炎疫苗研究进展  

The research progress of Hepatitis C vaccine

作　　者：姚敏[1] 李世林[1] 陈利民[1] 

机构地区：[1]中国医学科学院北京协和医学院输血研究所四川省输血传播疾病医学重点实验室,四川成都610052

出　　处：《中国输血杂志》2016年第11期1300-1302,共3页Chinese Journal of Blood Transfusion

摘　　要：丙型肝炎(Hepatitis C)是由丙型肝炎病毒感染引起的传染性肝病,更易慢性化,可导致肝脏慢性炎症坏死和纤维化,部分患者可发展为肝硬化甚至原发性肝癌。据世界卫生组织(WHO)统计,全球丙型肝炎慢性感染者约有1.3-1.5亿人,每年新发感染人数达300-400万例,每年大约有50万人死于丙型肝炎导致的终末期肝脏疾病。近年来,由于直接抗病毒药物(DAAs)的出现及在欧美发达国家广泛应用,丙型肝炎的治疗效果取得了长足进步,但仍存在价格昂贵以及病毒耐药等问题,因此,HCV疫苗的研制迫在眉睫。本文重点综述HCV疫苗研制进展。HCV（ Hepatitis C） is a blood-borne liver disease caused by the hepatitis C virus（ HCV） infection. Chronic infections may lead to chronic inflammation,necrosis and fibrosis of liver with potential to develop into cirrhosis and hepatocellular carcinoma. Hepatitis C is spread worldwide. According to the World Health Organization（ WHO）,there are approximately 130-150 million people currently infected with chronic hepatitis C in the world. In addition,the number of new infections is on the rise by 3,000,000-4,000,000 per year,and about 500,000 people died from end-stage liver diseases caused by HCV each year. The treatment regimen is mainly composed of pegylated-interferon alpha and ribavirin. Although directacting antiviral drugs（ DAAs） show better efficacy,some patients still do not respond optimally and DAAs are very expensive. As such,developing HCV vaccine is urgently needed. Although no HCV vaccine is available in the clinic at present,tremendous progress has been made in the field. This review will focus on the current status of HCV vaccine development.

关 键 词：丙型肝炎病毒 疫苗 临床试验 

分 类 号：R373.21[医药卫生—病原生物学] R457.2[医药卫生—基础医学]